Clinical

Articles

The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.

Real-World Data Suggest Systemic High-Dose and Intrathecal MTX Lower CNS Relapse Incidence for DLBCL

Videos

The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.

Matthew J. Matasar, MD, on the Clinical Implications of the Phase 3 CHRONOS-3 Study

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting

Patients treated in a multicenter trial experienced a median progression-free survival of 13.2 months with pembrolizumab versus 8.3 months in those receiving brentuximab vedotin.

Pembrolizumab Shows Better PFS Compared With Brentuximab Vedotin in R/R Classical Hodgkin Lymphoma

The lymphoma expert discussed how the addition of copanlisib to rituximab may add another treatment option for patients with relapsed indolent B-cell lymphomas.

Matthew J. Matasar, MD, Discusses Unmet Needs in Relapsed Indolent Non-Hodgkin Lymphoma

Even though the safety profile remained tolerable, treatment with lenalidomide plus R-CHOP did not improve progression-free survival compared with placebo plus R-CHOP for patients with activated B-cell-like subtype of DLBCL.

Lenalidomide Plus R-CHOP Did Not Improve PFS Compared With Placebo Plus R-CHOP for ABC-Type DLBCL

Data that led to the approval of umbralisib in patients with indolent non-Hodgkin lymphoma— including follicular lymphoma and marginal zone lymphoma—indicates favorable activity of the therapy versus other available PI3K inhibitors. 

Umbralisib Activity, Safety in Indolent Lymphomas Demonstrated in Phase 2b Trial 

Combination chemotherapy treatment followed by individualized PET4-guided therapy allowed some patients with unfavorable Hodgkin lymphoma to forego radiotherapy while maintaining efficacy.

Individualized PET4-Guided Treatment Allows Omission of Radiotherapy for Patients With Hodgkin Lymphoma

A phase 2 trial of single-agent AFM13, a bispecific tetravalent innate cell engager that binds to CD30, will continue following positive results of a preplanned interim futility analysis.

Registrational Trial of AFM13 Will Continue Following Success of Preplanned Interim Analysis

Data in The Lancet Oncology confirmed the standard of care as the optimal dosage to treat patients with indolent non-Hodgkin lymphoma.

Lymphoma | Topics